

# AHD-DSD implementation progress in Ethiopia

Mirtie Getachew

HIV and VH Prevention and Control Team Lead

**CQUIN 6<sup>th</sup> Annual Meeting**

December 6 – 9, 2022 | Durban, South Africa



# Presentation Outline

- Optimizing DSD implementation and increasing diversity of DSD models
- Programmatic updates on AHD implementation
  - CQUIN Advanced HIV Disease Capability Maturity Model Results
  - Resources developed to support AHD DSD
  - AHD reportable data elements
- Challenges
- Nest step

# Optimizing DSD implementation and increasing diversity of DSD models

- Conducted national DSD TWG regularly
- Tracked/monitored implementation of different DSD models focusing on site level practices, and quality of care in different DSD models
- Integrated all DSD tracking tools to DHIS2 system and EMR
  - Integrated DSD classification tools and registers into ART FUP, ART register, EMR, DHIS2 reporting
- Implementing DSD for AHD
- Prepared concept note and an implementation manual on new DSD models (DSD for ALHIV, DSD for MCH, DSD for 3MMD)

| Treatment CMM 2022                    | Ethiopia    |
|---------------------------------------|-------------|
| Policies                              | Dark Green  |
| Operational Guidance                  | Dark Green  |
| Diversity of DART services            | Yellow      |
| DSD Scale-up Plan                     | Yellow      |
| Coordination                          | Dark Green  |
| Meaningful Community Engagement       | Light Green |
| Training                              | Dark Green  |
| M&E System                            | Yellow      |
| Procurement and Stock Management      | Dark Green  |
| Less Intensive DART facility coverage | Dark Green  |
| Less Intensive DART Client Coverage   | Dark Green  |
| Advanced HIV Disease                  | Light Green |
| DART Services for Key Populations     | Orange      |
| TB/HIV                                | Orange      |
| Differentiated MCH Services           | Red         |
| Integration of FP into DART Models    | Orange      |
| Quality of DART Services              | Red         |
| Impact of DART Services               | Red         |

# Programmatic updates on AHD implementation - Nov 2022 (1)

## CQUIN Advanced HIV Disease Capability Maturity Model Results

|                                  |  |  |                              |                                    |
|----------------------------------|--|--|------------------------------|------------------------------------|
| Training                         |  |  |                              | Impact                             |
| Engagement of Recipients of Care |  |  |                              | Quality                            |
| Coordination                     |  |  |                              | M&E of AHD                         |
| SOPs                             |  |  |                              | Client Coverage 4: OI Management   |
| Implementation Plan              |  |  |                              | Client Coverage 3: OI Prophylaxis  |
| Guidelines                       |  |  | Supply Chain Management      | Client Coverage 2: OI Screening    |
| Policies                         |  |  | Diagnostic Capability 2: Ois | Client Coverage 1: Testing for AHD |
|                                  |  |  |                              | Facility Coverage                  |
|                                  |  |  |                              | Diagnostic Capability 1: AHD       |

Most mature domains Least mature domains



# Programmatic updates on AHD implementation - Nov 2022 (2)

- Developed AHD policy and guideline documents which also incorporated updates from the new CCM WHO GL
- Provided AHD DSD training in collaboration with ICAP
  - 2-day AHD DSD orientation provided for **160 HCWs** across the nation mapped by Hub/Spoke approach.
  - By integrating AHD into ART training curriculum additionally provided **training for 1000+ HCWs & clinical mentors**
- Printed and distributed job aides in support of AHD DSD and M&E tools to track implementation of AHD DSD to all RHBs and HFs
  - Onsite mentorship in AHD DSD and use of AHD resources provided during tool distribution
- Existing AHD laboratory service availability determined (e.g., CD4 testing) and mapped
  - Coordinated PIMA CD4 reagent functionality and reagent distribution with EPHI and partner
- AHD pharmaceutical supplies needs determined and procured by EPSA under the leadership of MOH
- Extracted and reviewed AHD DSD indicators from the EMR from February-August 2022


# Programmatic updates on AHD implementation - Nov 2022 (3)

AHD resources printed and distributed across the nation (4,391)

| AHD Resource  | Number Distributed |
|---|--------------------|
| AHD DSD Implementation manuals                            | 562                |
| Integrated DSD client screening tool & AHD screening tool | 562                |
| AHD DSD Service Provision Form                            | 381                |
| Comprehensive AHD Register                                | 264                |
| 3HP Flip Chart (Amharic for Provider)                     | 460                |
| AHD DSD Job Aids  | 2,162              |



# Basic AHD Package of Care for Hubs and spokes mapped



\*Kaposi sarcoma, PCP, Bacterial Sepsis, Toxoplasmosis

# AHD reportable data elements

| Indicator  |  |
|--|--|
| 1  | # of PLHIV seen in ART clinic  |
| 1.1  | # of PLHIV screened for DSD  |
| 1.1.1  | # of PLHIV enrolled in Advanced HIV Disease – AHD DSD model                |
| <b>A) Cryptococcus Meningitis (CM) screening</b>                 |  |
| 1  | # of PLHIV classified as more intensive care and tested for CD4 test       |
| 1.1  | # of PLHIV classified as more intensive care with CD4 count < 100 cells/ml |
| 2  | # Blood CrAg test performed  |
| 2.1  | # Blood CrAg positive  |
| 2.1.1  | # PLHIV with Sign and symptom of CM  |
| 2.1.1.1  | # CSF CrAg test performed  |
| 2.1.1.1.1  | # CSF result +ve   |
| <b>B) Cryptococcus Meningitis (CM) treatment and prophylaxis</b> |  |
| 5  | # initiated treatment on CM  |
| 6  | # initiated fluconazole pre-amptive/primary therapy                        |


| C) TB Screening                                   |                                     |
|---|-------------------------------------|
| 1   | # Screened for TB                   |
| 1.1   | # Suspect / Presumptive TB          |
| 2   | # Tested for CD4 test               |
| 2.1   | # PLHIV with CD4 <200 at inpatient  |
| 2.2   | # PLHIV with CD4 <100 at outpatient |
| 3   | # LF LAM performed                  |
| 3.1   | # LF LAM positive                   |
| <b>D) TB Treatment and TB prophylaxis therapy</b> |                                     |
| 4   | # Initiated TB treatment            |
| 5   | # initiated TPT                     |
| 5.1   | # 3HP                               |
| 5.2   | # 6HP                               |

| E) Other OI                    |  |
|--------------------------------|--|
| 6                              | # OIs classified and documented other than CM and TB |
| <b>F) Referral and linkage</b> |  |
| 7                              | # AHD referred for care and treatment to HUB sites   |
| <b>G) AHD DSD Model Change</b> |  |
| 8                              | # of clients changed AHD_DSD model to other DSD      |






# Steps to follow at sites for DSD and AHD recording tools



# Challenges

Delay in availing AHD commodities:

- No CrAg lateral flow assay (CrAg LFA) kit



- No Fluconazole for pre-emptive
- No medication for CCM treatment including Fluconazole for AmB, L-AmB/Ambisome, 5-FC



| Description of items                                  | Unites  | Quantity | status                               |
|---|---|----------|--------------------------------------|
| Serology – Cryptococcal Antigen Lateral Flow Assay –  | 25test s  | 1,795    | Tender under flotation.              |
| Fluconazole – 200mg – Tablet                          | 10x10   | 25,438   | Performance bond is not received yet |
| Fluconazole – 100mg – Tablet                          | 100   | 1,742    | Procurement through wambo            |
| Amphotericin B – 50mg in Vial – Injection (Liposomal) | Vial  | 11,367   | Procurement through wambo            |
| Flucytosine 500mg tablet                              | 100   | 1,198    | Procurement through wambo            |
| CD4 reagent (PIMA)                                    | Arrived in country and on distribution for sites with PIMA machine (<100 public HF's have PIMA machine) |          |                                      |
| CD4 reagent (FACSPRESTO)                              | Not yet arrived in country  |          |                                      |

## Next steps in AHD implementation

- Strengthen AHD implementation through the hub and spoke model through the engagement of all actors including the recipients of care
- Closely work with EPSS to avail AHD commodities
- Strengthen integrated reporting of all DSD models with regular monitoring of AHD implementation

# Tools

- [1. DSD M&E tools](#)
- [2. AHD Guidance materials prepared](#) – to be showcased at the CQUIN Tools Lab session on Friday

Thank you!

